PI3K/ AKT/mTOR Pathway Inhibitors in the Treatment of HR+/HER2- Metastatic Breast Cancer – Enduring Webcast

Description

Program Description

---

This enduring webcast will provide up-to-date, evidence-based information for diagnosing and treating patients with HR⁺/HER2^– metastatic Breast Cancer. The activity will focus on:

HR+/HER2^—MBC Testing: Hybrid capture-based next generation sequencing (NGS) assays (FoundationOne^®, FoundationOne^®CDx, or FoundationOne^®Liquid CDx) CLIA-certified, College of American Pathologists (CAP)-accredited laboratory (Foundation Medicine, Inc.) -Guideline update

• Comprehensive Genomic Profiling of ESR1, PIK3CA, AKT1, and PTEN in HR⁺/HER2^—MBC.

HR⁺/HER2^— MBC – First-line CDK4/6i combinations for HR⁺/HER2^—MBC with PIK3CA mutation (PIK3CAmt)

• Palbociclib plus fulvestrant versus placebo plus fulvestrant
• Abemaciclib plus fulvestrant versus placebo plus fulvestrant

HR⁺/HER2^—MBC – Second-line therapies for HR+/HER2^—MBC with PIK3CA/AKT1/PTEN alterations

• After progression on endocrine therapy plus CDK4/6i, second-line options for patients with PIK3CA/AKT1/PTEN alterations include inavolisib, alpelisib, capivasertib, and everolimus.
• Investigational therapies for HR+/HER2^—MBC with PIK3CA/AKT1/PTEN alterations – Gedatolisib
• Mutant-selective inhibitors – RELAY 2608, STX-478, LOXO-783, TOS-358

Adverse Effects (AEs) – Management of associated toxicities with the inhibitors of the PI3K/AKT/mTOR pathway

• Hyperglycemia and Hyperinsulinemia
• Stomatitis
• Maculopapular Rash
• Cardiovascular Events (CVAEs)

Intended Audience

---

Medical oncologists, pathologists, nurse practitioners, physician assistants, and nurses who diagnose and treat patients with HR⁺/HER2^– metastatic Breast Cancer.

Commercial Supporter

---

This activity is supported by an educational grant from AstraZeneca Pharmaceuticals